SCHEMBL9946137

SCHEMBL9946137

CC(=O)Oc1cccc(C2OC(C)(C)C(C)(C)O2)c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.51
LMNA P02545 1/20 0.51
CACNA1B Q00975 1/20 0.49
APBA1 Q02410 1/20 0.49
ACHE P22303 2/20 0.47
KIF11 P52732 1/20 0.45
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
ALDH1A1 P00352 3/20 0.42
HTT P42858 2/20 0.42
HSD17B10 Q99714 1/20 0.42
EPHX2 P34913 1/20 0.40
GAPDH P04406 1/20 0.39
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9946138 0.82 ALDH1A1 (0.49) CYP3A4LMNACACNA1BAPBA1KMT2A
SCHEMBL9946151 0.76 NR3C1 (0.41) ACHEKMT2AALDH1A1HTTHSD17B10
SCHEMBL13720739 0.76 CYP3A4 (0.56) CYP3A4LMNACACNA1BAPBA1ACHE
SCHEMBL249305 0.75 LMNA (0.76) CYP3A4LMNAACHEKMT2AMEN1
SCHEMBL17028900 0.75 LMNA (0.76) CYP3A4LMNAACHEKMT2AMEN1
SCHEMBL9946130 0.74 KMO (0.49) KMT2AMEN1ALDH1A1HSD17B10TP53
SCHEMBL9946141 0.74 GRIA2 (0.34) CYP3A4ALDH1A1
SCHEMBL31522974 0.73 CYP3A4 (0.53) CYP3A4LMNACACNA1BAPBA1ACHE
SCHEMBL1787633 0.73 CYP3A4 (0.53) CYP3A4LMNAACHEKMT2AMEN1
SCHEMBL1792243 0.72 KMO (0.54) CYP3A4LMNAACHEKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149693-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149693-A1 THERAPEUTIC COMPOUNDS HTR2C, GRK2, GRK3 CYP3A4 3867/4885LMNA 3453/4885CACNA1B 2515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.